Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
More about this company
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Sector: health
Conviction from: NASDAQ
52-week range: 13.5044.60
2 tracked filer(s) hold this · 1 opened, 1 added, 0 trimmed in 30-SEP-2026
Aggregate 13FScore 68 — mean of 2 scored holder(s) · buyers (new/add) avg 68. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-05-05 | SCHEDULE 13D | MOULDER LEON O JR | 5.1% | Med | filing |
| 2026-04-02 | SCHEDULE 13D/A | MOULDER LEON O JR | 4.8% | Low | filing |
| 2026-01-14 | SCHEDULE 13D | MOULDER LEON O JR | 5.2% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-05-18 | MOULDER LEON O JR (cluster of 2) | director+officer | 60,000 | $1,012,800 | Form 4 |
| 2026-04-29 | MOULDER LEON O JR (cluster of 2) | director+officer | 60,000 | $1,067,200 | Form 4 |
| 2026-04-01 | Fairmount Funds Management LLC (cluster of 2) | director | 150,000 | $3,000,000 | Form 4 |
| 2026-03-31 | MOULDER LEON O JR (cluster of 3) | director+officer | 54,000 | $1,021,140 | Form 4 |
| 2026-03-31 | Lu Hongbo (cluster of 3) | director | 75,000 | $1,500,000 | Form 4 |
| 2026-02-13 | Lu Hongbo (cluster of 3) | director | 25,985 | $584,662 | Form 4 |
| 2026-02-13 | Allen Patricia L (cluster of 3) | director | 19,860 | $499,746 | Form 4 |
| 2026-02-03 | MOULDER LEON O JR (cluster of 3) | director+officer | 57,000 | $1,023,720 | Form 4 |
| 2026-01-09 | MOULDER LEON O JR (cluster of 3) | director+officer | 100,000 | $1,639,000 | Form 4 |